作者
Laura Dickinson, Rohan Gurjar, Wolfgang Stöhr, Stefano Bonora, Andrew Owen, Antonio D’avolio, Adam Cursley, Jean-Michel Molina, Gerd Fäetkenheuer, Linos Vandekerckhove, Giovanni Di Perri, Anton Pozniak, Laura Richert, François Raffi, Marta Boffito
发表日期
2020/3/1
期刊
Journal of Antimicrobial Chemotherapy
卷号
75
期号
3
页码范围
628-639
出版商
Oxford University Press
简介
Objectives
NEAT001/ANRS143 demonstrated non-inferiority of once-daily darunavir/ritonavir (800/100 mg) + twice-daily raltegravir (400 mg) versus darunavir/ritonavir + tenofovir disoproxil fumarate/emtricitabine (245/200 mg once daily) in treatment-naive patients. We investigated the population pharmacokinetics of darunavir, ritonavir, tenofovir and emtricitabine and relationships with demographics, genetic polymorphisms and virological failure.
Methods
Non-linear mixed-effects models (NONMEM v. 7.3) were applied to determine pharmacokinetic parameters and assess demographic covariates and relationships with SNPs (SLCO3A1, SLCO1B1, NR1I2, NR1I3, CYP3A5*3, CYP3A4*22, ABCC2, ABCC10, ABCG2 and SCL47A1). The relationship between model-predicted darunavir AUC0–24 and C24 with time to virological failure was evaluated by Cox regression …
学术搜索中的文章
L Dickinson, R Gurjar, W Stöhr, S Bonora, A Owen… - Journal of Antimicrobial Chemotherapy, 2020